172 related articles for article (PubMed ID: 34943546)
1. Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer.
Huang YH; Lin PC; Su WC; Chan RH; Chen PC; Lin BW; Shen MR; Chen SH; Yeh YM
Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943546
[TBL] [Abstract][Full Text] [Related]
2. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
Kawaguchi Y; Kopetz S; Kwong L; Xiao L; Morris JS; Tran Cao HS; Tzeng CD; Chun YS; Lee JE; Vauthey JN
J Am Coll Surg; 2021 Aug; 233(2):272-284.e13. PubMed ID: 34111531
[TBL] [Abstract][Full Text] [Related]
3. Wild-type APC Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer.
Wang C; Ouyang C; Cho M; Ji J; Sandhu J; Goel A; Kahn M; Fakih M
Oncologist; 2021 Mar; 26(3):208-214. PubMed ID: 33230914
[TBL] [Abstract][Full Text] [Related]
4. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
[TBL] [Abstract][Full Text] [Related]
5. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
7. Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer.
Xu T; Zhang Y; Zhang J; Qi C; Liu D; Wang Z; Li Y; Ji C; Li J; Lin X; Hou T; Liu H; Zhang L; Han-Zhang H; Shen L; Wang X
Front Oncol; 2020; 10():568911. PubMed ID: 33194656
[TBL] [Abstract][Full Text] [Related]
8. Mutational Status of
Lahoz S; Rodríguez A; Fernández L; Gorría T; Moreno R; Esposito F; Oliveres H; Albiol S; Saurí T; Pesantez D; Riu G; Cuatrecasas M; Jares P; Pedrosa L; Pineda E; Postigo A; Castells A; Prat A; Maurel J; Camps J
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497403
[TBL] [Abstract][Full Text] [Related]
9. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
10. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
11. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
[TBL] [Abstract][Full Text] [Related]
12. Specific Mutations in APC, with Prognostic Implications in Metastatic Colorectal Cancer.
Peng H; Ying J; Zang J; Lu H; Zhao X; Yang P; Wang X; Li J; Gong Z; Zhang D; Wang Z
Cancer Res Treat; 2023 Oct; 55(4):1270-1280. PubMed ID: 37114476
[TBL] [Abstract][Full Text] [Related]
13. 'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patients.
Fang W; Radovich M; Zheng Y; Fu CY; Zhao P; Mao C; Zheng Y; Zheng S
Oncol Lett; 2014 Jun; 7(6):1761-1766. PubMed ID: 24932229
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
15. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
16. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer.
Yang J; Zhao S; Su J; Liu S; Wu Z; Ma W; Tang M; Wu J; Mao E; Han L; Liu M; Zhang J; Cao L; Shao J; Shang Y
Front Oncol; 2023; 13():1285508. PubMed ID: 38023196
[TBL] [Abstract][Full Text] [Related]
18. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
19. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.
Huang CW; Tsai HL; Chen YT; Huang CM; Ma CJ; Lu CY; Kuo CH; Wu DC; Chai CY; Wang JY
BMC Cancer; 2013 Dec; 13():599. PubMed ID: 24330663
[TBL] [Abstract][Full Text] [Related]
20. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]